Profusa Shares Scheduled to Reverse Split on Tuesday, July 7th (NASDAQ:PFSA)

Profusa, Inc. (NASDAQ:PFSA)’s stock is going to reverse split on the morning of Tuesday, July 7th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, July 6th.

Profusa Price Performance

NASDAQ PFSA remained flat at $0.09 during trading on Friday. 6,920,470 shares of the company’s stock traded hands, compared to its average volume of 7,584,541. The stock has a market capitalization of $435,710.00, a PE ratio of -0.00 and a beta of 0.47. Profusa has a 1-year low of $0.08 and a 1-year high of $180.00. The business’s 50-day simple moving average is $0.33 and its 200 day simple moving average is $2.53.

Profusa (NASDAQ:PFSA) last posted its earnings results on Friday, May 15th. The company reported ($2.05) earnings per share for the quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PFSA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Profusa has a consensus rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.